Mycobacterial aspartate 1-decarboxylase (PanD) (PanD)

Mycobacterial aspartate 1-decarboxylase (PanD) is an essential enzyme in Mycobacterium tuberculosis that catalyzes the decarboxylation of L-aspartate to produce beta-alanine [1.2.1, 1.4.1]. This reaction is the rate-limiting step in the biosynthesis of pantothenate (Vitamin B5), which serves as a precursor for Coenzyme A (CoA), a vital cofactor for energy metabolism and fatty acid synthesis [1.4.1, 1.4.2]. PanD has been identified as a primary target for the frontline anti-tuberculosis drug pyrazinamide (PZA) [1.1.1, 1.4.1]. PZA is a prodrug that is converted into its active form, pyrazinoic acid (POA), by the bacterial enzyme pyrazinamidase [1.4.1, 1.4.3]. POA binds to PanD and, rather than just inhibiting its enzymatic activity, triggers its degradation via the ClpC1-ClpP protease complex [1.1.1, 1.4.1]. This depletion of PanD leads to a deficiency in CoA, ultimately killing the bacteria, particularly the non-replicating persister cells that are often resistant to other antibiotics [1.3.2, 1.4.2]. Resistance to PZA is frequently associated with mutations in the panD gene, making it a significant focus for the development of next-generation anti-mycobacterial agents [1.4.2, 1.4.3]. Because PanD has no human homologs, it represents an attractive target for selective antibacterial therapy with minimal on-target toxicity [1.4.1, 1.4.3].

Other names

Aspartate 1-decarboxylaseL-aspartate alpha-decarboxylaseADCPanDAspartate decarboxylase

Pyrazinamide is a prodrug that is converted to its active form, pyrazinoic acid (POA), by the bacterial enzyme pyrazinamidase. POA binds to the PanD enzyme and triggers its degradation via the ClpC1-ClpP protease complex, while also acting as a weak competitive inhibitor of the enzyme's decarboxylase activity, leading to the depletion of Coenzyme A (CoA) [1.1.1, 1.3.1, 1.4.1].